Related by context. All words. (Click for frequent words.) 65 metastatic renal cell carcinoma 65 gastrointestinal stromal tumors 64 malignant pleural mesothelioma 63 gastrointestinal stromal tumors GIST 63 metastatic melanoma 62 metastatic colorectal cancer 62 glioblastoma 62 renal cell carcinoma 61 GISTs 61 hepatocellular carcinoma HCC 61 HER2 positive breast cancer 61 CLL 60 recurrent NSCLC 60 gastrointestinal stromal tumor GIST 60 HER2 positive 60 carcinoma 60 NSCLC 60 gastrointestinal stromal tumor 60 basal cell carcinoma BCC 59 chronic lymphocytic leukemia CLL 59 metastatic cancer 59 CTCL 59 bone metastasis 59 glioblastoma multiforme GBM 59 imatinib resistant 59 medullary thyroid cancer 59 pancreatic adenocarcinoma 59 advanced NSCLC 58 metastatic malignant 58 unresectable 58 Gleevec resistant 58 metastatic RCC 58 pancreatic NET 58 hepatocellular carcinoma 58 pancreatic neuroendocrine tumors 58 vandetanib 57 Glioblastoma Multiforme 57 hepatocellular cancer 57 sarcoma 57 mRCC 57 leukemia ALL 57 sarcomas 57 anti angiogenic therapy 57 Metastatic 57 Li Fraumeni Syndrome 57 carcinoid tumors 57 lymphoma CTCL 57 follicular lymphoma 57 resectable 57 stage IIIB 57 gastric cancer 57 EGFR inhibitors 57 metastatic prostate cancer 57 neoadjuvant treatment 57 solid tumors 57 metastatic breast cancer 57 cutaneous squamous cell carcinoma 57 malignancies 57 heavily pretreated 56 TACE 56 Imatinib 56 Acute Myelogenous Leukemia AML 56 leukemia CLL 56 differentiated thyroid 56 imatinib 56 neuroendocrine tumors 56 axitinib 56 leukemia AML 56 liver metastases 56 neoadjuvant therapy 56 metastatic colon cancer 56 sorafenib 56 Malignant Melanoma 56 adenocarcinoma 56 prostate cancer mCRPC 56 metastatic malignant melanoma 56 Kit CD# positive 56 relapsed ovarian cancer 56 tumors GIST 56 Acute Leukemia 56 sunitinib 56 fallopian tube carcinoma 56 malignant melanoma 56 soft tissue sarcomas 56 recurrent glioblastoma multiforme 55 leiomyosarcoma 55 Sorafenib 55 neoadjuvant chemotherapy 55 relapsing multiple sclerosis 55 metastatic 55 metastatic disease 55 PNET 55 Hepatocellular Carcinoma HCC 55 melanoma 55 cutaneous melanoma 55 advanced metastatic renal 55 irinotecan chemotherapy 55 carcinomas 55 gastrointestinal cancers 55 Irinotecan 55 recurrent glioblastoma 55 Carcinoma 55 tyrosine kinase inhibitors 55 metastatic gastric 55 malignancy 55 sorafenib Nexavar 55 Chronic Myeloid Leukemia 55 stage IIIA 55 GBM 55 brain metastases 55 glioblastoma multiforme 55 LHON 55 tumors 55 transplantation HSCT 55 Glioma 55 Hodgkin Lymphoma 55 refractory AML 55 HER2 positive metastatic breast 55 Myelofibrosis 55 PCa 55 colorectal liver metastases 55 Lymphoma 55 SCCHN 55 nonmetastatic 55 non squamous 55 recurrent GBM 55 metastatic GIST 55 Leukemias 55 micrometastases 55 erlotinib 55 chronic myelogenous leukemia CML 55 Surgical resection 55 carcinoid 55 biliary tract cancer 55 GIST tumors 55 ErbB2 positive 54 superficial bladder cancer 54 renal tumors 54 Glioblastoma 54 mCRC 54 Cetuximab 54 Gefitinib 54 chronic myeloid leukemia CML 54 castration resistant prostate cancer 54 acute myelogenous leukemia AML 54 squamous cell carcinoma SCC 54 Gleevec 54 Neoadjuvant 54 cell carcinoma 54 mycophenolate mofetil 54 Multiple Myeloma 54 carcinoid cancer 54 medulloblastoma 54 Lenalidomide 54 histologies 54 imatinib Gleevec 54 pancreatic carcinoma 54 CMV disease 54 HER2 overexpression 54 relapsing remitting multiple sclerosis 54 cell lymphoma CTCL 54 metastases 54 pertuzumab 54 squamous cell carcinoma 54 vismodegib 54 Follicular Lymphoma 54 hypereosinophilic syndrome 54 Waldenstrom macroglobulinemia 54 vWD 54 colorectal cancer 54 imatinib mesylate 54 thymoma 54 lymphomas 54 relapsed refractory 54 lymphoid malignancies 54 temozolomide 54 prostate cancer CRPC 54 mutated KRAS 54 HCV infected 54 chemoradiotherapy 54 non metastatic osteosarcoma 54 HER2 + 54 pancreatic islet cell 54 recurrent colorectal cancer 54 HERCEPTIN 54 Chronic lymphocytic leukemia 54 Metastatic Colorectal Cancer 54 cancer mCRC 54 cediranib 54 resistant ovarian cancer 53 tyrosine kinase inhibitor 53 bevacizumab Avastin 53 multiple myeloma 53 pleural mesothelioma 53 breast carcinomas 53 nonsmall cell lung cancer 53 metastatic neuroendocrine tumors 53 Dasatinib 53 indolent NHL 53 acute promyelocytic leukemia 53 invasive candidiasis 53 Trastuzumab 53 cutaneous T 53 nonmelanoma skin cancers 53 Mantle Cell Lymphoma 53 chemoradiation 53 TKI therapy 53 KRAS mutation 53 DLBCL 53 unresectable stage 53 gastric adenocarcinoma 53 bendamustine 53 malignant gliomas 53 pheochromocytoma 53 sunitinib malate 53 metastatic colorectal 53 bevacizumab Avastin ® 53 5FU 53 platinum refractory 53 bone metastases 53 Acute lymphoblastic leukemia 53 imatinib Gleevec ® 53 brain tumors 53 defibrotide 53 Chronic Myelogenous Leukemia 53 metastatic lesions 53 trabectedin 53 cisplatin chemotherapy 53 myeloproliferative disorder 53 meningiomas 53 dasatinib Sprycel 53 squamous cell 53 Pertuzumab 53 adjuvant therapy 53 relapsed CLL 53 urothelial carcinoma 53 VFEND 53 lymphoma 53 erlotinib Tarceva ® 53 Acute Myeloid Leukemia 53 dasatinib 53 IV melanoma 53 metastatic kidney 53 cetuximab 53 recurrent glioma 53 Acute Myeloid Leukemia AML 53 Anaplastic 53 IV NSCLC 53 Fludarabine 53 breast carcinoma 53 docetaxel Taxotere ® 53 TTF Therapy 53 myelofibrosis 53 inoperable pancreatic cancer 53 Erlotinib 53 Acute Myeloid Leukaemia AML 53 Chronic Lymphocytic Leukemia CLL 53 Cholangiocarcinoma 53 hormone refractory prostate cancer 53 Colorectal 53 cholangiocarcinoma 53 recurrent ovarian cancer 53 gliomas 53 squamous cell cancer 53 breast cancers 53 cell lung cancer 53 advanced hepatocellular carcinoma 53 relapsed GBM 53 tyrosine kinase inhibitors TKIs 53 receptor tyrosine kinase inhibitor 53 preoperative chemotherapy 53 ADPKD 53 relapsed refractory multiple myeloma 52 Crizotinib 52 Rituxan rituximab 52 Burkitt lymphoma 52 gefitinib Iressa 52 Idiopathic Pulmonary Fibrosis 52 glioblastoma tumors 52 EGFR TKI 52 ovarian cancer 52 IRESSA 52 Chronic Lymphocytic Leukemia 52 Epratuzumab 52 HCV genotype 1 52 pegylated liposomal doxorubicin 52 cetuximab Erbitux ® 52 GRASPA ® 52 Tumours 52 carboplatin paclitaxel 52 T Cell Lymphoma 52 non squamous NSCLC 52 Metastatic breast cancer 52 GvHD 52 nasopharyngeal cancer 52 XELOX 52 tumor recurrence 52 papillary 52 allogeneic SCT 52 lung tumors 52 mucinous 52 radioimmunotherapy 52 pazopanib 52 taxane therapy 52 ependymoma 52 adjuvant chemotherapy 52 Glioblastoma Multiforme GBM 52 colorectal carcinoma 52 relapsing MS 52 Hodgkin lymphoma HL 52 Velcade bortezomib 52 angiogenesis inhibitor 52 ribavirin RBV 52 paclitaxel carboplatin 52 hematologic disorders 52 Glioblastoma multiforme 52 DIPG 52 alveolar rhabdomyosarcoma 52 lung metastases 52 soft tissue sarcoma 52 malignant growths 52 colorectal cancers 52 paraganglioma 52 Myelodysplastic Syndromes 52 cutaneous T cell 52 EGFr 52 stage IIIB IV 52 trastuzumab 52 Cell Lung Cancer 52 Bladder Cancer 52 sorafenib Nexavar ® 52 gefitinib 52 paragangliomas 52 situ CIS 52 obatoclax 52 imatinib resistance 52 LHRH receptor positive 52 HDACi 52 gastric cancers 52 biologic therapy 52 carcinoid tumor 52 relapsed SCLC 52 Cutaneous T 52 HRPC 52 anaplastic astrocytoma 52 chlorambucil 52 BAY #-# 52 ZACTIMA 52 IMGN# 52 essential thrombocythemia 52 Myelodysplastic Syndrome MDS 52 CHOP chemotherapy 52 ToGA 52 Non Hodgkins lymphoma 52 squamous cell cancers 52 EGFR mutation 52 myelodysplastic syndrome MDS 52 CTEPH 52 metastatic bladder 52 free survival PFS 52 decitabine 52 prostate adenocarcinoma 52 adenocarcinomas 52 Sezary syndrome 52 bevacizumab 52 anaplastic 52 daunorubicin 52 abiraterone 52 topotecan 52 locoregional 52 familial amyloidotic polyneuropathy FAP 52 thromboembolic events 52 pancreatic cancers 52 squamous cell carcinomas 52 mTOR inhibitor 51 transthyretin amyloidosis 51 recurrent glioblastoma multiforme GBM 51 Doxil ® 51 alkylating agent 51 imatinib mesylate Gleevec 51 Torisel 51 HCV infection 51 basal cell carcinomas 51 Non Hodgkin Lymphoma 51 Castration Resistant Prostate Cancer 51 squamous 51 imatinib therapy 51 acute leukemias 51 Gastrointestinal Stromal Tumors 51 anaplastic thyroid cancer 51 Rituximab 51 synovial sarcoma 51 gemcitabine 51 Acute myeloid leukemia 51 neoplasia 51 Papillary 51 transitional cell carcinoma 51 follicular lymphomas 51 Nexavar sorafenib 51 Esophageal Cancer 51 ASCT 51 chemotherapeutic agents 51 rituximab 51 nasopharyngeal carcinoma 51 EGFR mutation positive 51 Voreloxin 51 Gleevec imatinib mesylate 51 ALCL 51 non resectable 51 acute myeloid 51 urothelial cancer 51 achieved sustained virological 51 metastatic CRC 51 Gorlin syndrome 51 severe oral mucositis 51 mTOR inhibitors 51 Multiple Myeloma MM 51 azacitidine 51 cilengitide 51 squamous cell lung cancer 51 T#I [002] 51 SCH # 51 Follicular lymphoma 51 hormone receptor positive 51 dasatinib Sprycel ® 51 hematological malignancy 51 anticancer therapy 51 BRAF inhibitor 51 allogeneic bone marrow 51 evaluating tivozanib 51 Osteosarcoma 51 bladder carcinoma 51 colorectal cancer CRC 51 nilotinib 51 neoplasm 51 gemcitabine Gemzar 51 chronic eosinophilic leukemia 51 recurrent prostate cancer 51 stage IIIb IV 51 glioblastoma GBM 51 vorinostat 51 castrate resistant prostate cancer 51 prostate cancer PCa 51 Relapsed Refractory 51 mutated KRAS gene 51 Hepatocellular Carcinoma 51 refractory ovarian cancer 51 MALT lymphoma 51 BRAF V#E mutation 51 bladder cancers 51 malignant lymphoma 51 vemurafenib 51 GW# [003] 51 Lupus Nephritis 51 cell carcinoma RCC 51 Acute Promyelocytic Leukemia 51 heavily pretreated patients 51 metastatic tumors 51 taxane chemotherapy 51 prostate cancer HRPC 51 KRAS wild 51 neoplasms 51 advanced pancreatic neuroendocrine 51 lupus nephritis 51 cisplatin resistant 51 Hodgkin lymphoma NHL 51 IIIB NSCLC 51 saphenous vein graft 51 Benign Prostatic Hyperplasia BPH 51 PTLD 51 relapsed MM 51 mycosis fungoides 51 CML CP 51 panobinostat 51 plaque psoriasis 51 colorectal cancer liver metastases 51 Cell Lymphoma 51 B Cell Lymphoma 51 FLT3 51 locoregional disease 51 anti TNF 51 follicular thyroid cancer 51 Meningiomas 51 AP# [003] 51 mCRC patients 51 indolent lymphomas 51 Herceptin trastuzumab 51 autologous transplants 51 castrate resistant 51 tuberous sclerosis complex 51 Novartis Gleevec 51 refractory CLL 51 Squamous Cell Carcinoma 51 refractory NSCLC 51 GBMs 51 CLL SLL 51 ximelagatran 51 Enzastaurin 51 metastatic cancers 51 BR.# 51 epithelial tumors 51 biliary cancer 51 pulmonary metastases 51 K RAS 51 Proxinium TM 51 acute lymphoblastic leukemia 51 cancers 51 ixabepilone 51 hepatic metastases 51 operable breast cancer 51 EGFR mutations 51 Fludara 51 antiplatelet therapy 51 TMC# C# 51 OncoVEX GM CSF 51 prostate cancer CaP 51 pan HDAC inhibitor 51 PLX# 51 vinorelbine 51 metastatic renal cell 51 curative therapy 51 papillary RCC 51 Tyrosine Kinase Inhibitors 50 cabazitaxel 50 proliferative diabetic retinopathy 50 trans retinoic acid 50 FDG PET imaging 50 glioblastomas 50 temsirolimus 50 DAPT 50 Renal cell carcinoma 50 Severe Sepsis 50 tigecycline 50 liver cancer 50 basal cell 50 unresectable tumors 50 Metastases 50 CYT# potent vascular disrupting 50 ovarian carcinoma 50 EGF receptor 50 SUTENT 50 cetuximab Erbitux R 50 refractory colorectal cancer 50 FDG-PET/CT 50 nilotinib Tasigna 50 Nilotinib 50 iclaprim 50 myeloablative 50 Taxotere ® 50 completely resected 50 minimally symptomatic 50 anti leukemic 50 TEMODAL 50 epithelial ovarian 50 refractory chronic myeloid 50 Amrubicin 50 invasive aspergillosis 50 NSABP 50 Renal Cell Carcinoma RCC 50 B CLL 50 actinic keratoses 50 multikinase inhibitor 50 mapatumumab 50 capecitabine 50 FOLFIRI alone 50 Soft Tissue Sarcoma 50 acute coronary syndromes ACS 50 p# biomarker 50 Barrett esophagus 50 pT2 50 interstitial cystitis IC 50 myelodysplastic syndrome 50 cytokine refractory 50 Pemetrexed 50 Glioblastoma multiforme GBM 50 essential thrombocythemia ET 50 myasthenia gravis MG 50 thalidomide Thalomid 50 TYKERB 50 Xanafide 50 Diffuse Large B 50 gemcitabine carboplatin 50 nonalcoholic steatohepatitis NASH 50 carboplatin 50 BRAF mutation 50 cytoreductive nephrectomy 50 IIIA NSCLC 50 K ras mutations 50 Gleevec imatinib 50 haematopoietic 50 haematological cancers 50 endometrial cancers 50 biochemical recurrence 50 EGFR TKIs 50 Ewing sarcoma 50 complete cytogenetic 50 Acute Myelogenous Leukemia 50 melanomas 50 PCNSL 50 adenoma 50 Everolimus 50 follicular NHL 50 standard chemotherapy regimen 50 peritoneal cancer 50 Philadelphia Chromosome Positive 50 chronic myeloid 50 acoustic neuromas 50 CBLC# 50 gastrointestinal stromal tumors GISTs 50 pediatric malignancies 50 tumor shrinkage 50 Xeloda capecitabine 50 systemic lupus erythematosus SLE 50 huN# DM1 50 Inflammatory Breast Cancer 50 recurrent squamous cell carcinoma 50 distant metastases 50 PRoFESS 50 elacytarabine 50 Non Hodgkin lymphoma 50 myelofibrosis polycythemia vera 50 grade gliomas 50 histologically confirmed 50 ERCC1 50 nucleoside analog 50 YONDELIS 50 angiogenesis inhibition 50 myeloid metaplasia 50 Hydroxyurea 50 invasive ductal carcinoma 50 Aplidin 50 EGFR tyrosine kinase inhibitors 50 Basal cell carcinoma 50 Acute Lymphoblastic Leukemia 50 FSGS 50 TOP2A 50 carcinoma HNSCC 50 metastatic castration resistant 50 cytogenetic abnormalities 50 Ceflatonin 50 KIT mutations 50 olaparib 50 neuroendocrine cancers 50 IDH1 mutation 50 chronic HBV infection 50 Myeloma 50 Adenocarcinoma 50 localized renal 50 Epidermal Growth Factor Receptor 50 Myelodysplastic Syndrome 50 thyroid nodules 50 rectal cancers 50 activating mutations 50 myeloproliferative diseases 50 SPINK1 50 NOXAFIL 50 relapsed leukemia 50 adenomatous 50 renal cell carcinomas 50 cell carcinomas 50 T#I mutation 50 neoplastic lesions 50 node metastases 50 FOLFOX4 50 retinoblastoma 50 ovarian tumors 50 radiofrequency ablation RFA 50 Pancreatic Cancer 50 extracranial 50 allogeneic hematopoietic stem cell 50 PsA 50 chemotherapeutic regimen 50 DCVax ® Brain 50 anti angiogenic agents 50 Omacetaxine 50 prostate cancers 50 assessing T DM1 50 ankylosing spondylitis AS 50 T DM1 50 neuroblastoma tumors 50 grade glioma 50 null responder 50 Myelodysplastic syndrome 50 FOLFIRI 50 ASCUS 50 Revlimid lenalidomide 50 NF2 50 phase IIb clinical 50 Chronic Myelogenous Leukemia CML 50 evaluable 50 colorectal neoplasms 50 small lymphocytic lymphoma 50 epithelial ovarian cancer 50 bortezomib Velcade R 50 myeloproliferative 50 adalimumab 50 AA amyloidosis 50 liver metastasis 50 fibroadenomas 50 Merkel cell carcinoma 50 Orphan Drug 50 subependymal giant cell 50 Cutaneous Melanoma 50 Cloretazine 50 NMIBC 50 Retinitis Pigmentosa RP 50 membranous nephropathy 50 Ceplene/IL-2 50 cardiac allograft vasculopathy 49 lobular carcinoma 49 seminoma 49 Renal Cell Carcinoma 49 HER2 49 distant metastasis 49 TORISEL 49 Zolinza 49 HER2 positive cancers 49 cinacalcet 49 prostate carcinomas 49 estrogen receptor progesterone receptor 49 metastatic breast 49 chronic hepatitis B. 49 Tykerb 49 interstitial pneumonia 49 sunitinib Sutent 49 GVHD 49 fosbretabulin 49 neoadjuvant 49 PSADT 49 iniparib 49 Halaven 49 plus gemcitabine 49 idiopathic pulmonary fibrosis IPF 49 colorectal tumors 49 Vectibix 49 Vandetanib 49 invasive breast cancer 49 Unresectable 49 secondary hyperparathyroidism 49 MAGE A3 49 fluorouracil 49 refractory acute myeloid 49 MabCampath 49 raltegravir 49 anticancer agents 49 ccRCC 49 prostate carcinoma 49 refractory angina 49 haematologic malignancies 49 oblimersen 49 VZV 49 gastroesophageal junction 49 lumiliximab 49 Phase #/#a trial 49 castration resistant 49 refractory CML 49 virotherapy 49 unresectable locally advanced 49 microtubule targeting 49 HuMax CD4 49 brain tumor glioblastoma multiforme 49 OPAXIO 49 entecavir 49 epirubicin 49 hepatitis C HCV 49 acute ischemic stroke 49 oncolytic vaccine 49 juvenile idiopathic arthritis 49 Adenomas 49 PARP inhibitor 49 metastatic pancreatic cancer 49 Metastatic Renal Cell Carcinoma 49 refractory CTCL 49 cytotoxic chemotherapy 49 STRIDE PD 49 Glivec 49 metachronous 49 acute myeloid leukemia 49 chronic periodontitis 49 Zarnestra 49 cancer 49 allogeneic HSCT 49 WT1 49 ThermoDox R 49 chemotherapeutic agent 49 Gliomas 49 relapsing remitting 49 systemic lupus erythematosus 49 Alemtuzumab 49 liver resection 49 pituitary adenomas 49 ISF# 49 SWOG 49 urothelial bladder cancer 49 colorectal carcinomas 49 multikinase inhibitors 49 proteasome inhibitor 49 xenograft models 49 IV malignant melanoma 49 nodular BCC 49 docetaxel 49 disease progression 49 haematological malignancies 49 HoFH 49 Preclinical Models 49 Squamous 49 Wilms tumor 49 metastatic NSCLC 49 dacarbazine 49 metastatic pancreatic 49 KRAS mutations 49 androgen independent 49 Avastin bevacizumab 49 mCRPC 49 IMA# 49 Wegener granulomatosis 49 ZOLINZA 49 ocular melanoma 49 allogeneic stem cell 49 Boceprevir 49 clinically localized prostate 49 Brentuximab Vedotin SGN 49 transplantation HCT 49 doxorubicin Adriamycin 49 estramustine 49 lapatinib 49 ara C 49 primitive neuroectodermal tumor 49 Natalizumab 49 anthracyclines 49 relapsed multiple myeloma 49 CR nPR 49 chronic lymphocytic leukemia 49 nilotinib Tasigna ® 49 vulvar intraepithelial neoplasia 49 peritoneal carcinomatosis 49 medulloblastomas 49 Cystinosis 49 lymphoblastic leukemia 49 Sutent 49 Peginterferon alfa 2b 49 neuroblastoma 49 pegylated interferon 49 ADVEXIN 49 pain palliation 49 acute GvHD 49 Systemic Sclerosis 49 enzastaurin 49 multiple myeloma MM 49 ovarian cancers 49 colorectal metastases 49 Etanercept 49 chondrosarcoma 49 osteosarcomas 49 MPS VI 49 EUS FNA 49 Sprycel dasatinib 49 tocilizumab 49 Novartis Afinitor 49 R0 resection 49 idarubicin 49 plus dexamethasone 49 lung adenocarcinoma 49 everolimus 49 5 fluorouracil 49 invasive ductal 49 chronic ITP patients 49 AVASTIN 49 embryonal rhabdomyosarcoma 49 AGTR1 49 EGFRvIII 49 trabedersen 49 Glioblastomas 49 familial ALS 49 bronchogenic carcinoma 49 precancerous cervical lesions 49 adjuvant radiation 49 metastatic basal cell 49 acute myeloid leukemia AML 49 median PFS 49 FVIIa 49 pegfilgrastim 49 BMS # 49 Ofatumumab 49 cell lymphoma ALCL 49 capecitabine Xeloda 49 Candida infection 49 DMARD 49 graft dysfunction 49 curable cancers 49 TroVax ® 49 Kaposi sarcoma 49 vasculitis 49 MGUS 49 standard chemotherapy regimens 49 contralateral breast 49 leukoencephalopathy 49 cetuximab Erbitux 49 advanced unresectable 49 afatinib 49 uveal melanoma 49 chronic myelogenous leukemia 49 Aflibercept 49 FOLFOX regimen 49 malignant lesions 49 ALND 49 sarcomatoid 49 HCV genotype 49 relapsed AML 49 sirolimus 49 pilocytic astrocytomas 49 Langerhans cell histiocytosis 49 fludarabine 49 liposomal doxorubicin 49 complete remissions 49 MEK inhibitors 49 samalizumab 49 gynecologic cancer 49 tuberous sclerosis TS 49 prostate tumor 49 depsipeptide 49 ELOXATIN 49 JAK2 V#F 49 Rate ORR 49 PARP inhibitors 49 HCV infections 49 hepatitis C genotype 49 Tarceva erlotinib 49 LBH# 49 chimeric monoclonal antibody 49 concurrent chemoradiation 49 Bortezomib 49 metastatic carcinoma 49 ATIR 49 EoE 49 noninfectious uveitis 49 docetaxel Taxotere 49 HNSCC 49 Sym# 49 common hematologic malignancy 49 acute promyelocytic leukemia APL 49 vinca alkaloids 49 EGFR HER2 49 Doxorubicin 49 Carboplatin 49 complete cytogenetic response 49 CA4P 49 candidemia 49 tanespimycin 49 RRMS 49 Pharmacokinetics PK 49 HSCT 49 EGFR expressing 49 interferon alfa 49 APTIVUS r 49 chronic ITP 49 idiopathic myelofibrosis 49 astrocytoma 49 papillary renal cell carcinoma 49 neuroendocrine carcinoma 49 calcineurin inhibitors 49 micrometastasis 49 IV metastatic melanoma 49 Non Hodgkin 49 Pixantrone 49 HLA DR2 49 lung adenocarcinomas 49 breast tumors 49 Folotyn 49 K ras 49 CALGB # [001] 49 neuroblastomas 48 IMC #B 48 SIR Spheres microspheres 48 CanAg 48 Abatacept 48 Basal cell 48 hypersensitivity reaction 48 Aliskiren 48 Vidaza azacitidine 48 refractory gastrointestinal stromal 48 nodal metastasis 48 pulmonary hypertension PH 48 premalignant 48 malignant tumors 48 octreotide LAR 48 anticancer therapies 48 severe sepsis 48 Advanced Melanoma 48 Dacogen injection 48 glioma 48 therapeutic regimens 48 operable pancreatic cancer 48 Thrombolysis 48 vascular disrupting agent 48 Fludara ® 48 Arranon 48 EGFR 48 Degarelix